<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820857</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL14_0442</org_study_id>
    <secondary_id>2016-001305-16</secondary_id>
    <nct_id>NCT02820857</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer</brief_title>
  <acronym>BEVANEC</acronym>
  <official_title>Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive&#xD;
      neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and&#xD;
      digestive. The gastroentero-pancreatic NECs (GEP-NEC) represent 7-21% of all of the NENs.&#xD;
&#xD;
      Recent data on the initial presentation of GEP-NEC have been reported in two retrospective&#xD;
      studies and a French cohort study. No standard second-line treatment has been defined for&#xD;
      NECs. Despite a very negative prognosis, these NECs have a certain amount of&#xD;
      chemosensitivity, close to that of bronchial NECs. Multiple-drug therapies such as Folfiri,&#xD;
      or Folfox, or single drug treatments such as temozolomide are the proposed options but with a&#xD;
      low level of proof Bevacizumab associated with a cytotoxic chemotherapy has shown promising&#xD;
      results in well differentiated neuroendocrine tumors (NET), known for being hypervascular.&#xD;
      The efficacy of bevacizumab has also been suggested in patients with NEC, but never in the&#xD;
      context of a phase II study. Its combination with Folfiri is efficient and well tolerated in&#xD;
      metastatic colorectal cancer. The combination Folfiri-bevacizumab potentially represents an&#xD;
      optimized treatment compared to chemotherapy with only Folfiri. No phase II or III studies&#xD;
      have reported results for these patients, and no on-going phase II or III trial have been&#xD;
      identified to date.&#xD;
&#xD;
      The main objective of this study is to show that, after the failure of a first-line&#xD;
      chemotherapy using platinum-etoposide, the combination Folfiri-bevacizumab allows significant&#xD;
      prolongation of overall survival in adult patients with GEP-NEC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">September 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>The primary endpoint is the proportion of patients alive 6 months after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Neuroendocrine Carcinomas</condition>
  <arm_group>
    <arm_group_label>Folfiri-bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folfiri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfiri-bevacizumab</intervention_name>
    <description>Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)</description>
    <arm_group_label>Folfiri-bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfiri</intervention_name>
    <description>Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)</description>
    <arm_group_label>Folfiri</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged ≥ 18 years old,&#xD;
&#xD;
          -  Poorly differentiated neuroendocrine carcinoma (NEC) from a gastrointestinal tract&#xD;
             (from esophagus to anal canal) and biliopancreatic primary or an unknown primary&#xD;
             cancer, locally advanced and/or metastatic,&#xD;
&#xD;
          -  Centralized review of the diagnostic by a consulting pathologist specializing in NET&#xD;
             (TENPATH network),&#xD;
&#xD;
          -  Recommendation of a second-line chemotherapy after progression, documented using the&#xD;
             RECIST criteria v.1.1, and after a first-line chemotherapy treatment by cisplatin (or&#xD;
             carboplatin) + etoposide or in the event of progression in the 6 months following the&#xD;
             discontinuation of this first-line treatment,&#xD;
&#xD;
          -  Recommendation of a second-line chemotherapy for the refractory patient or&#xD;
             contraindicated for platinum-etoposide chemotherapy&#xD;
&#xD;
          -  Patients presenting at least one measurable target lesion according to the RECIST&#xD;
             criteria v.1.1, in an area not previously irradiated,&#xD;
&#xD;
          -  General condition ≤ 2 (WHO),&#xD;
&#xD;
          -  Patient of child bearing age accepting to use an effective contraception during&#xD;
             treatment and until 6 months after the last administration,&#xD;
&#xD;
          -  Patient who signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Relating to the tumor, the patient, and previous treatment:&#xD;
&#xD;
               -  Well differentiated neuroendocrine tumor&#xD;
&#xD;
               -  Mixed tumor, except if the NEC component is &gt; 70%, the patient is eligible,&#xD;
&#xD;
               -  First-line chemotherapy other than cisplatin (or carboplatin) and etoposide,&#xD;
&#xD;
               -  All malignant disease in the three years before randomization, with the exception&#xD;
                  of basal cell carcinoma or in situ cancer treated for curative purposes,&#xD;
&#xD;
               -  A pregnant or breastfeeding woman,&#xD;
&#xD;
               -  Lack of efficient contraception (for men or women of reproductive age),&#xD;
&#xD;
               -  All medical, geographical, social, and psychological conditions or a legal&#xD;
                  situation that will not allow the patient to finish the study or sign an informed&#xD;
                  consent form,&#xD;
&#xD;
          2. Relating to the chemotherapy (Folfiri):&#xD;
&#xD;
               -  Any of the following uncontrolled progressive diseases in the 6 months before&#xD;
                  randomization: liver failure, renal insufficiency, respiratory distress,&#xD;
                  congestive heart failure (NYHA III-IV), unstable angina, myocardial infarction,&#xD;
                  significant arrhythmia,&#xD;
&#xD;
               -  Known deficiency in dihydropyrimidine dehydrogenase,&#xD;
&#xD;
               -  Known Gilbert's syndrome,&#xD;
&#xD;
               -  Total bilirubin level &gt;1.5x the upper limit of normal (ULN); AST (Aspartate&#xD;
                  transaminase) and/or ALT (Alanine transaminase) &gt;5x ULN; TP &lt;50%;&#xD;
&#xD;
               -  Neutrophils &lt;1.5x109/l, platelets &lt;100x109/l, hemoglobin &lt;9 g/dl,&#xD;
&#xD;
               -  Chronic uncontrolled diarrhea, unresolved intestinal occlusion or subocclusion,&#xD;
&#xD;
               -  History of anaphylactic reaction or known intolerance to atropine (sulfate) or to&#xD;
                  loperamide or to antiemetics administered in association with Folfiri,&#xD;
&#xD;
               -  All treatment with concomitant anticonvulsive agents, CYP3A4 inducers (phenytoin,&#xD;
                  phenobarbital, carbamazepine), discontinued for at least 7 days,&#xD;
&#xD;
          3. Relating to bevacizumab:&#xD;
&#xD;
               -  Uncontrolled brain metastases (by local treatment),&#xD;
&#xD;
               -  All uncontrolled progressive disease within 1 month prior to randomization: grade&#xD;
                  3-4 gastrointestinal bleeding (peptic ulcer, erosive esophagitis or gastritis),&#xD;
                  infectious disease or intestinal inflammation, diverticulitis, pulmonary embolism&#xD;
                  or other uncontrolled thromboembolic event,&#xD;
&#xD;
               -  Uncontrolled high blood pressure defined as a systolic blood pressure &gt;140 mmHg&#xD;
                  or diastolic pressure &gt;90 mmHg,&#xD;
&#xD;
               -  Patients receiving anticoagulant treatment with an unstable dose of a vitamin K&#xD;
                  antagonist treatment, and/or having an abnormal INR (&gt;3) in the four weeks before&#xD;
                  the randomization,&#xD;
&#xD;
               -  Verified proteinuria above or equal to 1g/24 hours measured from 24 hours of&#xD;
                  urine if the urinary protein dipstick control is above or equal to 2+,&#xD;
&#xD;
               -  Creatinine clearance (MDRD) &lt;50 ml/min.&#xD;
&#xD;
               -  Hypersensitivity to the active substance or to any of the excipients.&#xD;
&#xD;
               -  Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other&#xD;
                  recombinant human or humanised antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas WALTER, MD</last_name>
    <phone>4 72 11 73 98</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.walter@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie PROME</last_name>
    <phone>4 72 11 62 03</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.prome@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent HAUTEFEUILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume ROQUIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume ROQUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie et Radiothérapie, Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MINEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent MINEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastroentérologie et Oncologie Digestive, Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence MARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence MARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, APHP</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia HENTIC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivia HENTIC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastroentérologie, CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iradj SOBHANI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Iradj SOBHANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie et Oncologie Digestive, CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Côme LEPAGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Côme LEPAGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentéologie, Hôpital Michallon, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoire GRANGER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Victoire GRANGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Cancérologie Urologique et Digestive, Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid EL HAJBI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Farid EL HAJBI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de cancérologie médicale - Groupe des tumeurs endocrines, Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu SARABI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu SARABI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas WALTER, MD</last_name>
      <phone>4 72 11 73 98</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.walter@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas WALTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département d'Oncologie Médicale, Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia NICCOLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia NICCOLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Timone, APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13365</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia DAHAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laetitia DAHAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale, Hôpital Saint Eloi, CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric ASSENAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric ASSENAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara DAUVOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Barbara DAUVOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département d'Oncologie Médicale, Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pauline AFCHAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Salpêtrière, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Service de Gastroentérologie, Hôpital Cochin, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain CORIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain CORIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Européen Georges Pompidou, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline LEPERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline LEPERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital Haut Lévêque, CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis SMITH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Denis SMITH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Régional de Cancérologie, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie FERRU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie FERRU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie et Cancérologie, Hôpital Robert Debré, CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CADIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume CADIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, Hôpital Pontchaillou, CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid LIEVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Astrid LIEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastroentérologie, CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric DI FIORE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric DI FIORE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastro-Entérologie, Hôpital Nord, CHU de ST-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas WILLIET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas WILLIET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale, Hôpital Civil, CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Emmanuel KURTZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Emmanuel KURTZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Endocrinienne, Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MALKA, MD</last_name>
    </contact>
    <investigator>
      <last_name>David MALKA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroentero-pancreatic neuroendocrine carcinomas</keyword>
  <keyword>Second-line treatment</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Folfiri</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

